牛牛AI助理已提取核心訊息
Intelligent Bio Solutions Inc. (INBS), a medical technology company, announced a significant year-over-year revenue increase in its fiscal second quarter and six-month financial results ending December 31, 2023. The company reported a 114% revenue increase for the quarter and a 337% increase for the six-month period, attributed to the acquisition of Intelligent Fingerprinting Ltd and growth in the Asia Pacific business. Despite the revenue growth, INBS experienced a net loss increase from $1.63 million to $4.39 million for the six months compared to the previous year, primarily due to the combined results of operations post-acquisition. The company also highlighted its expansion into the New Zealand market and increased market share in existing regions. Notably, INBS's laboratory partner received accreditation from the National Association of Testing Authorities for its fingerprint confirmatory drug testing procedure. The company's President and CEO, Harry Simeonidis, expressed optimism about the growth trajectory and the potential for further expansion in the Asia-Pacific region. INBS ended the quarter with cash and cash equivalents of approximately $1.12 million.
Intelligent Bio Solutions Inc. (INBS), a medical technology company, announced a significant year-over-year revenue increase in its fiscal second quarter and six-month financial results ending December 31, 2023. The company reported a 114% revenue increase for the quarter and a 337% increase for the six-month period, attributed to the acquisition of Intelligent Fingerprinting Ltd and growth in the Asia Pacific business. Despite the revenue growth, INBS experienced a net loss increase from $1.63 million to $4.39 million for the six months compared to the previous year, primarily due to the combined results of operations post-acquisition. The company also highlighted its expansion into the New Zealand market and increased market share in existing regions. Notably, INBS's laboratory partner received accreditation from the National Association of Testing Authorities for its fingerprint confirmatory drug testing procedure. The company's President and CEO, Harry Simeonidis, expressed optimism about the growth trajectory and the potential for further expansion in the Asia-Pacific region. INBS ended the quarter with cash and cash equivalents of approximately $1.12 million.
醫療技術公司智能生物解決方案公司（INBS）宣佈，其第二財季收入同比大幅增長，截至2023年12月31日的六個月財務業績。該公司報告稱，本季度收入增長114％，六個月內增長337％，這歸因於對智能指紋有限公司的收購以及亞太業務的增長。儘管收入增長，但與去年相比，INBS六個月的淨虧損從163萬美元增加到439萬美元，這主要是由於收購後的綜合經營業績。該公司還強調了其向新西蘭市場的擴張以及在現有地區的市場份額的增加。值得注意的是，INBS的實驗室合作伙伴因其指紋確認藥物測試程序獲得了全國測試機構協會的認證。該公司總裁兼首席執行官哈里·西蒙尼迪斯對亞太地區的增長軌跡和進一步擴張的潛力表示樂觀。INBS在本季度末的現金及現金等價物約爲112萬美元。
醫療技術公司智能生物解決方案公司（INBS）宣佈，其第二財季收入同比大幅增長，截至2023年12月31日的六個月財務業績。該公司報告稱，本季度收入增長114％，六個月內增長337％，這歸因於對智能指紋有限公司的收購以及亞太業務的增長。儘管收入增長，但與去年相比，INBS六個月的淨虧損從163萬美元增加到439萬美元，這主要是由於收購後的綜合經營業績。該公司還強調了其向新西蘭市場的擴張以及在現有地區的市場份額的增加。值得注意的是，INBS的實驗室合作伙伴因其指紋確認藥物測試程序獲得了全國測試機構協會的認證。該公司總裁兼首席執行官哈里·西蒙尼迪斯對亞太地區的增長軌跡和進一步擴張的潛力表示樂觀。INBS在本季度末的現金及現金等價物約爲112萬美元。
有用
沒用